Renovacor (NYSE:RCOR) and Kymera Therapeutics (NASDAQ:KYMR) Financial Contrast

Renovacor (NYSE:RCORGet Rating) and Kymera Therapeutics (NASDAQ:KYMRGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Renovacor and Kymera Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Renovacor 0 4 1 0 2.20
Kymera Therapeutics 0 4 6 0 2.60

Renovacor presently has a consensus price target of $20.00, indicating a potential upside of 574.54%. Kymera Therapeutics has a consensus price target of $43.40, indicating a potential upside of 59.44%. Given Renovacor’s higher possible upside, equities research analysts clearly believe Renovacor is more favorable than Kymera Therapeutics.

Risk and Volatility

Renovacor has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.

Insider and Institutional Ownership

45.8% of Renovacor shares are owned by institutional investors. 14.4% of Renovacor shares are owned by insiders. Comparatively, 17.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Renovacor and Kymera Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Renovacor N/A N/A -$14.10 million ($0.73) -4.06
Kymera Therapeutics $72.83 million 20.51 -$100.22 million ($2.94) -9.26

Renovacor has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Renovacor, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Renovacor and Kymera Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Renovacor N/A -62.88% -48.90%
Kymera Therapeutics -334.72% -34.20% -26.40%

Summary

Kymera Therapeutics beats Renovacor on 7 of the 13 factors compared between the two stocks.

About Renovacor

(Get Rating)

Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.

About Kymera Therapeutics

(Get Rating)

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Receive News & Ratings for Renovacor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovacor and related companies with MarketBeat.com's FREE daily email newsletter.